{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:51:42Z","timestamp":1760853102992,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.amjmed.2005.01.071","type":"journal-article","created":{"date-parts":[[2005,6,29]],"date-time":"2005-06-29T08:59:57Z","timestamp":1120035597000},"page":"695-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Update on the drug treatment of hypertension in patients with cardiovascular disease"],"prefix":"10.1016","volume":"118","author":[{"given":"William B.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2003","series-title":"Heart Disease and Stroke Statistics \u2014 2004 Update","key":"10.1016\/j.amjmed.2005.01.071_bib1"},{"key":"10.1016\/j.amjmed.2005.01.071_bib2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJMoa010273","article-title":"Characteristics of patients with uncontrolled hypertension in the United States","volume":"345","author":"Hyman","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359;","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib5","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib6","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib7","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.35.5.1021","article-title":"Clinical Advisory Statement","volume":"35","author":"Izzo","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2005.01.071_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib10","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension","volume":"21","year":"2003","journal-title":"J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/01.HYP.35.2.539","article-title":"Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification","volume":"35","author":"Ogden","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2005.01.071_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction","volume":"21","author":"Staessen","year":"2003","journal-title":"J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMp030057","article-title":"Ambulatory blood-pressure monitoring in clinical practice","volume":"348","author":"White","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1161\/01.CIR.0000056521.67546.AA","article-title":"Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives","volume":"107","author":"Kario","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.01.071_bib16","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa022273","article-title":"Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension","volume":"348","author":"Clement","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib17","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and \u03b2-blockers on cardiovascular morbidity and mortality in hypertension","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib25","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.01.071_bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.1994.03520010045030","article-title":"Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study","volume":"272","author":"Bikkina","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/ajh\/2.8.650","article-title":"Importance of left ventricular mass as a predictor of cardiovascular morbidity in hypertension","volume":"8","author":"Devereux","year":"1989","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib29","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1161\/hc4201.097944","article-title":"Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension","volume":"104","author":"Verdecchia","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.01.071_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","article-title":"Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study","volume":"108","author":"Okin","year":"2003","journal-title":"Circulation"},{"issue":"11 Pt 1","key":"10.1016\/j.amjmed.2005.01.071_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0895-7061(03)01018-5","article-title":"Changes in cardiovascular risk by reduction of left ventricular mass in hypertension","volume":"16","author":"Verdecchia","year":"2003","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.amjmed.2005.01.071_bib32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by reduction of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.01.071_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.STR.0000126208.14181.DD","article-title":"Blood pressure and stroke","volume":"35","author":"Lawes","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2005.01.071_bib35","first-page":"2120","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"359","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib36","unstructured":"MOrbidity and mortality after Stroke - Eprosartan compared with nitrendipine for Secondary prevention (MOSES) trial. Presented at European Society of Cardiology, Munich, Germany, August 30, 2004."},{"key":"10.1016\/j.amjmed.2005.01.071_bib37","unstructured":"Sacco RL, Diener HC, Yusuf S. Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS). Presented at the 29th International Stroke Conference, San Diego, California, February 5, 2004."},{"key":"10.1016\/j.amjmed.2005.01.071_bib38","unstructured":"2004 USRDS Annual Data Report. Available at: http:\/\/www.usrds.org\/2004\/pdf\/02_incid_prev_04.pdf. Accessed September 29, 2004."},{"key":"10.1016\/j.amjmed.2005.01.071_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.25.4.587","article-title":"Early predictors of 15-year end-stage renal disease in hypertensive patients","volume":"25","author":"Perry","year":"1995","journal-title":"Hypertension"},{"issue":"3 Pt 2","key":"10.1016\/j.amjmed.2005.01.071_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-8703(99)70312-1","article-title":"Elevated systolic blood pressure and risk of cardiovascular and renal disease","volume":"138","author":"He","year":"1999","journal-title":"Am Heart J."},{"key":"10.1016\/j.amjmed.2005.01.071_bib41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.164.16.1737","article-title":"Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart","volume":"164","author":"Lim","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000145180.38707.84","article-title":"Pathophysiology of hypertensive renal damage. Implications for therapy","volume":"44","author":"Bidani","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2005.01.071_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib45","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1592\/phco.23.15.1611.31962","article-title":"A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension","volume":"23","author":"Park","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2005.01.071_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.ajkd.2004.03.022","article-title":"The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension","volume":"44","author":"Barzilay","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.amjmed.2005.01.071_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11906-004-0053-1","article-title":"Clinical importance of microalbuminuria in diabetes and hypertension","volume":"6","author":"Bakris","year":"2004","journal-title":"Curr Hypertens Rep."},{"key":"10.1016\/j.amjmed.2005.01.071_bib48","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib49","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib50","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.071_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0002-9343(99)00444-1","article-title":"Management of patients with hypertension and diabetes mellitus","volume":"108","author":"White","year":"2000","journal-title":"Am J Med."},{"key":"10.1016\/j.amjmed.2005.01.071_bib52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2005.01.071_bib53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.071_bib55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305002536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305002536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:38:20Z","timestamp":1757579900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305002536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0002934305002536"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.071","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the drug treatment of hypertension in patients with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}